Analysts/Institutional Investor Meet/Con. Call Updates

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 November 9, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Transcript of Post Results Conference Call held on November 4, 2026 Ref: Our Intimation dated October 30, 2026 With reference to the captioned subject, please find enclosed herewith the transcript of the Conference Call held on November 4, 2026. The same is also uploaded on the Company's website i.e. https://www.amanta.co.in/investor- meet You are requested to take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA COMPANY SECRETARY & COMPLIANCE OFFICER Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 “Amanta Healthcare Limited Q2 & H1 FY27 Earnings Conference Call” November 04, 2026 MANAGEMENT: MR. BHAVESH PATEL – CHAIRMAN AND MANAGING DIRECTOR – AMANTA HEALTHCARE LIMITED MR. PARAS MEHTA – CHIEF FINANCIAL OFFICER – AMANTA HEALTHCARE LIMITED MODERATOR: MS. SOUMYA – GO INDIA ADVISORS LLP Page 1 of 15 Amanta Healthcare Limited November 04, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Amanta Healthcare Limited Q2 H1 FY '27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Soumya from Go India Advisors. Thank you, and over to you, madam. Soumya Chhajed: Good day, everyone, and welcome to Q2 and H1 FY '27 earnings call of Amanta Healthcare Limited. We have on call with us Mr. Bhavesh Patel, Chairman and Managing Director; Mr. Paras Mehta, Chief Financial Officer. We must remind you that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks pertaining to the business. I now request the management to take us through the same and provide some more insight on the quarter and half year gone by. And post that, we'll open the floor for Q&A. Thank you, and over to you, sir. Bhavesh Patel: Namaste and good afternoon, everyone. Thank you for joining us for the Amanta Healthcare Q2 FY '27 earnings call. On behalf of the management, I would like to sincerely thank our shareholders, customers, health care partners, leaders, and employees for their continued trust and support. Q2 FY '27 has been a quarter of delivery for Amanta. Our top line grew by 17% year-on-year and profit grew even faster than revenue. Our CFO, Shri Paras Mehta will take you through the numbers in details later. Let me focus on what we have achieved so far and where our next phase of growth will come from. First, SteriPort Line 3 is live, is operational. We commissioned it in the first week of September 2026 at our existing Kheda facility, taking our SteriPort capacity up by about 75%, from INR6.6 crores per year to roughly INR11.6 crores. SteriPort is built on advanced ISBM technology, continues to see strong customer acceptance for its advantages in stability, safety, and reduced patient risk with demand across high-value therapies such as onco care, critical care, anesthesia, and pediatrics. We expect Line 3 to reach full ramp-up within the next quarter. SteriPort Line 3 is having some technological advancements such as process automation, server controls, robotic operations, and it reduces human intervention. Though this requires skilled operations and supervision, it makes operation of our new line more efficient and reliable. Second, our 10.8 megawatt captive solar plant has been generating power since the end of Q1 FY '27. This is a structural cost advantage that will reduce our power cost every year by also strengthening our ESG profile. Third, we have strengthened our balance sheet considerably. Our debt-to-equity ratio has come down from 3.5x in FY '23 to about 1.1 in FY '26, giving us the financial headroom to fund our next phase of growth with discipline. Our annual repayment of debt is scheduled at roughly Page 2 of 15 Amanta Healthcare Limited November 04, 2026 INR35 crores, including solar loans. Our growth levers. Going forward, 3 pillars are working together to drive growth. The first is market depth. We are expanding our wallet share with complex dosage forms and niche molecules across anti-infectives, respiratory, and ophthalmics. And we are deepening our presence in advanced markets. In Q2 FY '27, approximately 32% of our revenue came from international markets. The second is manufacturing scale. After SteriPort, our next expansion is in small volume parenterals, where capacity will rise by roughly 52%, from INR20.9 crores to roughly INR31 crores during Q1 FY '28. SVP new line is primarily aimed at using our current capacity and F&D activities to strengthen offerings for inhalation solutions and ophthalmics. And the third is efficiency. Alongside solar, our new lines share existing infrastructure, workforce, and utilities. As volume scale, this gives us meaningful operating leverage and better absorption of fixed costs. The future outlook. With these investments, we have set ourselves a clear 2-year aim, revenue growth of 20%-plus CAGR and EBITDA margins of 25%-plus. We believe we are well positioned to deliver this. The capacity is already in place, SVP is under construction. The cost savings are structural and the balance sheet is ready to support the growth. Over the coming quarters, our key milestones will be the full ramp-up of SteriPort Line 3 and commissioning of expanded SVP facility in Q1 FY '28. We remain confident in the long-term opportunity for Amanta Healthcare and committed to creating sustainable value for all our stakeholders. With that I would like to hand over the call to our CFO, Shri Paras Mehta. Paras Mehta: Thank you. Good afternoon, everyone, and welcome to Q2 FY '27 result call of Amanta Healthcare. First, we would like to update you about the quarter performance, that is Q2 FY '27. During the quarter, revenue from operations stood at INR83.1 crore, up by 17% year-on-year from INR71 crore of the same quarter of last year. EBITDA for the quarter is also up by about 22%, which is INR18 crore, and EBITDA margin has remained healthy at 21.6% despite all challenges of overhead and new raw material price pressure. EBITDA grew little faster than revenue, reflecting better absorption of fixed cost as well as benefit, which started from the solar operations. Finance cost was INR6 crore, depreciation INR5 crore, that is up by 13%. As new capacity has come on the stream, so full depreciation has been provided during the quarter. Same way, the interest for the solar project term loan has already started from last quarter itself. So during the quarter, finance cost includes the interest towards the solar coming up. After depreciation and interest, profit before tax, and exceptional item has grown to about 39%, to INR7 crore. This is highest during the quarter, since listing. Profit after tax has stood at INR4.86 crores, up by 26% year-on-year basis with a PAT margin of about 6%. Coming to half year, which includes the current quarter that is half year ended September 2027. For the first half of current financial year, revenue recorded is INR152 crores, rather INR151.9 crores precisely, up by 12% year-on-year basis. Page 3 of 15 Amanta Healt [Showing first 8,000 characters — download PDF for full document]